Unknown NA INTERVENTIONAL 2-arm NCT02643589

Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell Transplantation

Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis

Sponsor: Central South University Xiangya Hospital

Conditions Hematopoietic Stem Cell Transplantation

Interventions ATG

Updated 7 times since 2017 Last updated: Dec 30, 2015 Started: Jun 30, 2013 Primary completion: Jun 30, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Hematopoietic Stem Cell Transplantation, this trial is ongoing. The trial is conducted by Central South University Xiangya Hospital and has accumulated 7 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jul 2023 — Jul 2024 [monthly]

Unknown Status NA
Jan 2021 — Jul 2023 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA

▶ Show 2 earlier versions

Feb 2018 — Jun 2018 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jan 2017 — Feb 2018 [monthly]

Recruiting NA

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Central South University Xiangya Hospital
Fujian Medical University
Nanfang Hospital, Southern Medical University
Peking University People's Hospital

Data source: Nanfang Hospital, Southern Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China